|
1
|
Margolin G, Petrykowska HM, Jameel N, Bell
DW, Young AC and Elnitski L: Robust Detection of DNA
Hypermethylation of ZNF154 as a Pan-Cancer Locus with in Silico
Modeling for Blood-Based Diagnostic Development. J Mol Diagn.
18:283–298. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
González-Masiá JA, García-Olmo D and
García-Olmo DC: Circulating nucleic acids in plasma and serum
(CNAPS): Applications in oncology. Onco Targets Ther. 6:819–832.
2013.PubMed/NCBI
|
|
3
|
Metais P and Mandel P: Les acides
necleiques du plasma sanguin chez l'Homme. C R Acad Sci Paris.
142:241–243. 1948.
|
|
4
|
Fleischhacker M and Schmidt B: Circulating
nucleic acids (CNAs) and cancer - a survey. Biochim Biophys Acta.
1775:181–232. 2007.PubMed/NCBI
|
|
5
|
Crowley E, Di Nicolantonio F, Loupakis F
and Alberto Bardelli A: Liquid biopsy: monitoring cancer-genetics
in the blood. Nature Reviews Clinical Oncology. 10:472–484. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Schwarzenbach H, Hoon DS and Pantel K:
Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev
Cancer. 11:426–437. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Stroun M, Lyautey J, Lederrey C,
Olson-Sand A and Anker P: About the possible origin and mechanism
of circulating DNA apoptosis and active DNA release. Clin Chim
Acta. 313:139–142. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Stroun M, Anker P, Maurice P, Lyautey J,
Lederrey C and Beljanski M: Neoplastic characteristics of the DNA
found in the plasma of cancer patients. Oncology. 46:318–322.
1989.PubMed/NCBI
|
|
9
|
García-Olmo DC, Ruiz-Piqueras R and
García-Olmo D: Circulating nucleic acids in plasma and serum
(CNAPS) and its relation to stem cells and cancer metastasis: State
of the issue. Histol Histopathol. 19:575–583. 2004.PubMed/NCBI
|
|
10
|
van der Vaart M and Pretorius PJ:
Circulating DNA. Its origin and fluctuation. Ann N Y Acad Sci.
1137:18–26. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lo YM, Chan LY, Lo KW, Leung SF, Zhang J,
Chan AT, Lee JC, Hjelm NM, Johnson PJ and Huang DP: Quantitative
analysis of cell-free Epstein-Barr virus DNA in plasma of patients
with nasopharyngeal carcinoma. Cancer Res. 59:1188–1191.
1999.PubMed/NCBI
|
|
12
|
Yang HJ, Liu VW, Tsang PC, Yip AM, Tam KF,
Wong LC, Ng TY and Ngan HY: Quantification of human papillomavirus
DNA in the plasma of patients with cervical cancer. Int J Gynecol
Cancer. 14:903–910. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Anker P, Mulcahy H, Chen XQ and Stroun M:
Detection of circulating tumour DNA in the blood (plasma/serum) of
cancer patients. Cancer Metastasis Rev. 18:65–73. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Giacona MB, Ruben GC, Iczkowski KA, Roos
TB, Porter DM and Sorenson GD: Cell-free DNA in human blood plasma:
Length measurements in patients with pancreatic cancer and healthy
controls. Pancreas. 17:89–97. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nagata S, Nagase H, Kawane K, Mukae N and
Fukuyama H: Degradation of chromosomal DNA during apoptosis. Cell
Death Differ. 10:108–116. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Holdenrieder S and Stieber P: Apoptotic
markers in cancer. Clin Biochem. 37:605–617. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nagata S: DNA degradation in development
and programmed cell death. Annu Rev Immunol. 23:853–875. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Atamaniuk J, Ruzicka K, Stuhlmeier KM,
Karimi A, Eigner M and Mueller MM: Cell-free plasma DNA: A marker
for apoptosis during hemodialysis. Clin Chem. 52:523–526. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fournié GJ, Courtin JP, Laval F, Chalé JJ,
Pourrat JP, Pujazon MC, Lauque D and Carles P: Plasma DNA as a
marker of cancerous cell death. Investigations in patients
suffering from lung cancer and in nude mice bearing human tumours.
Cancer Lett. 91:221–227. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen Z, Fadiel A, Naftolin F, Eichenbaum
KD and Xia Y: Circulation DNA: Biological implications for cancer
metastasis and immunology. Med Hypotheses. 65:956–961. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Anker P, Stroun M and Maurice PA:
Spontaneous release of DNA by human blood lymphocytes as shown in
an in vitro system. Cancer Res. 35:2375–2382. 1975.PubMed/NCBI
|
|
22
|
Stroun M, Lyautey J, Lederrey C, Mulcahy
HE and Anker P: Alu repeat sequences are present in increased
proportions compared to a unique gene in plasma/serum DNA: Evidence
for a preferential release from viable cells? Ann N Y Acad Sci.
945:258–264. 2001.PubMed/NCBI
|
|
23
|
Alix-Panabières C, Schwarzenbach H and
Pantel K: Circulating tumor cells and circulating tumor DNA. Annu
Rev Med. 63:199–215. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bidard FC, Weigelt B and Reis-Filho JS:
Going with the flow: From circulating tumor cells to DNA. Sci
Transl Med. 5:207ps14. 2013.
|
|
25
|
Ignatiadis M and Dawson SJ: Circulating
tumor cells and circulating tumor DNA for precision medicine: Dream
or reality? Ann Oncol. 25:2304–2313. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Roth C, Kasimir-Bauer S, Pantel K and
Schwarzenbach H: Screening for circulating nucleic acids and
caspase activity in the peripheral blood as potential diagnostic
tools in lung cancer. Mol Oncol. 5:281–291. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Altimari A, Grigioni AD, Benedettini E,
Gabusi E, Schiavina R, Martinelli A, Morselli-Labate AM, Martorana
G, Grigioni WF and Fiorentino M: Diagnostic role of circulating
free plasma DNA detection in patients with localized. Am J Clin
Pathol. 129:756–762. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Schwarzenbach H: Circulating nucleic acids
as biomarkers in breast cancer. Breast Cancer Res. 15:2112013.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ono A, Fujimoto A, Yamamoto Y, Akamatsu S,
Hiraga N, Imamura M, Kawaoka T, Tsuge M, Abe H, Hayes CN, et al:
Circulating Tumor DNA Analysis for Liver Cancers and Its Usefulness
as a Liquid Biopsy. Cellular and Molecular Gastroenterology and
Hepatology. 1:516–534. 2015. View Article : Google Scholar
|
|
30
|
Ho MW: Intercommunication via circulating
nucleic acids. Science in Society. 42:46–48. 2009.
|
|
31
|
Gardiner C, Harrison P, Belting M, Böing
A, Campello E, Carter BS, Collier ME, Coumans F, Ettelaie C, van Es
N, et al: Extracellular vesicles, tissue factor, cancer and
thrombosis - discussion themes of the ISEV 2014 Educational Day. J
Extracell Vesicles. 4:269012015.PubMed/NCBI
|
|
32
|
Garcia-Murillas I, Schiavon G, Weigelt B,
Ng C, Hrebien S, Cutts RJ, Cheang M, Osin P, Nerurkar A, Kozarewa
I, et al: Mutation tracking in circulating tumor DNA predicts
relapse in early breast cancer. Sci Transl Med. 7:302ra133.
2015.
|
|
33
|
Umetani N, Giuliano AE, Hiramatsu SH,
Amersi F, Nakagawa T, Martino S and Hoon DS: Prediction of breast
tumor progression by integrity of free circulating DNA in serum. J
Clin Oncol. 24:4270–4276. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hamakawa T, Kukita Y, Kurokawa Y, Miyazaki
Y, Takahashi T, Yamasaki M, Miyata H, Nakajima K, Taniguchi K and
Takiguchi S: Monitoring gastric cancer progression with circulating
tumour DNA. Br J Cancer. 112:352–356. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bettegowda C, Sausen M, Leary RJ, Kinde I,
Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, et al:
Detection of circulating tumor DNA in early- and late-stage human
malignancies. Sci Transl Med. 6:224ra24. 2014.
|
|
36
|
Figg WD II and Reid J: Monitor tumor
burden with circulating tumor DNA. Cancer Biol Ther. 14:697–698.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Roschewski M, Dunleavy K, Pittaluga S,
Kong K, Shovlin M, Jaffe ES, Staudt LM, Lai C, Chen CC, Zheng J, et
al: Monitoring of Circulating Tumor DNA As Minimal Residual Disease
in Diffuse Large B-Cell Lymphoma. Blood. 124:1392014.
|
|
38
|
De Mattos-Arruda L, Weigelt B, Cortes J,
Won HH, Ng CKY, Nuciforo P, Bidard FC, Aura C, Saura C, Peg V, et
al: Capturing intra-tumor genetic heterogeneity by de novo mutation
profiling of circulating cell-free tumor DNA: A proof-of-principle.
Ann Oncol. 25:1729–1735. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Siravegna G and Bardelli A: Genotyping
cell-free tumor DNA in the blood to detect residual disease and
drug resistance. Genome Biol. 15:4492014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yoon KA, Park S, Lee SH, Kim JH and Lee
JS: Comparison of circulating plasma DNA levels between lung cancer
patients and healthy controls. J Mol Diagn. 11:182–185. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Diehl F, Schmidt K, Choti MA, Romans K,
Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo SA, et al:
Circulating mutant DNA to assess tumor dynamics. Nat Med.
14:985–990. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
García-Olmo DC, Samos J, Picazo MG,
Asensio AI, Toboso I and García-Olmo D: Release of cell-free DNA
into the bloodstream leads to high levels of non-tumor plasma DNA
during tumor progression in rats. Cancer Lett. 272:133–140. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Frattini M, Gallino G, Signoroni S,
Balestra D, Battaglia L, Sozzi G, Leo E, Pilotti S and Pierotti MA:
Quantitative analysis of plasma DNA in colorectal cancer patients:
a novel prognostic tool. Ann N Y Acad Sci. 1075:185–190. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Catarino R, Ferreira MM, Rodrigues H,
Coelho A, Nogal A, Sousa A and Medeiros R: Quantification of free
circulating tumor DNA as a diagnostic marker for breast cancer. DNA
Cell Biol. 27:415–421. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Sozzi G, Conte D, Leon M, Ciricione R, Roz
L, Ratcliffe C, Roz E, Cirenei N, Bellomi M, Pelosi G, et al:
Quantification of free circulating DNA as a diagnostic marker in
lung cancer. J Clin Oncol. 21:3902–3908. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Sai S, Ichikawa D, Tomita H, Ikoma D, Tani
N, Ikoma H, Kikuchi S, Fujiwara H, Ueda Y and Otsuji E:
Quantification of plasma cell-free DNA in patients with gastric
cancer. Anticancer Res 27 (4C). 2747–2751. 2007.
|
|
47
|
Tomita H, Ichikawa D, Ikoma D, Sai S, Tani
N, Ikoma H, Fujiwara H, Kikuchi S, Okamoto K, Ochiai T, et al:
Quantification of circulating plasma DNA fragments as tumor markers
in patients with esophageal cancer. Anticancer Res 27 (4C).
2737–2741. 2007.
|
|
48
|
Atamaniuk J, Vidotto C, Tschan H, Bachl N,
Stuhlmeier KM and Müller MM: Increased concentrations of cell-free
plasma DNA after exhaustive exercise. Clin Chem. 50:1668–1670.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Lo YM, Rainer TH, Chan LY, Hjelm NM and
Cocks RA: Plasma DNA as a prognostic marker in trauma patients.
Clin Chem. 46:319–323. 2000.PubMed/NCBI
|
|
50
|
Jacobs EL and Haskell CM: Clinical use of
tumor markers in oncology. Curr Probl Cancer. 15:299–360.
1991.PubMed/NCBI
|
|
51
|
Wang BG, Huang HY, Chen YC, Bristow RE,
Kassauei K, Cheng CC, Roden R, Sokoll LJ, Chan DW and Shih IeM:
Increased plasma DNA integrity in cancer patients. Cancer Res.
63:3966–3968. 2003.PubMed/NCBI
|
|
52
|
Umetani N, Kim J, Hiramatsu S, Reber HA,
Hines OJ, Bilchik AJ and Hoon DS: Increased integrity of free
circulating DNA in sera of patients with colorectal or
periampullary cancer: Direct quantitative PCR for ALU repeats. Clin
Chem. 52:1062–1069. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Umetani N, Giuliano AE, Hiramatsu SH,
Amersi F, Nakagawa T, Martino S and Hoon DS: Prediction of breast
tumor progression by integrity of free circulating DNA in serum. J
Clin Oncol. 24:4270–4276. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Schwarzenbach H, Müller V, Stahmann N and
Pantel K: Detection and characterization of circulating
microsatellite-DNA in blood of patients with breast cancer. Ann N Y
Acad Sci. 1022:25–32. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Sunami E, Shinozaki M, Higano CS, Wollman
R, Dorff TB, Tucker SJ, Martinez SR, Mizuno R, Singer FR and Hoon
DS: Multimarker circulating DNA assay for assessing blood of
prostate cancer patients. Clin Chem. 55:559–567. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Esteller M, Sanchez-Cespedes M, Rosell R,
Sidransky D, Baylin SB and Herman JG: Detection of aberrant
promoter hypermethylation of tumor suppressor genes in serum DNA
from non-small cell lung cancer patients. Cancer Res. 59:67–70.
1999.PubMed/NCBI
|
|
57
|
Wong IH, Lo YM, Zhang J, Liew CT, Ng MH,
Wong N, Lai PB, Lau WY, Hjelm NM and Johnson PJ: Detection of
aberrant p16 methylation in the plasma and serum of liver cancer
patients. Cancer Res. 59:71–73. 1999.PubMed/NCBI
|
|
58
|
Thierry AR, Mouliere F, El Messaoudi S,
Mollevi C, Lopez-Crapez E, Rolet F, Gillet B, Gongora C, Dechelotte
P and Robert B: Clinical validation of the detection of KRAS and
BRAF. Nat Med. 20:430–435. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Etheridge A, Gomes CP, Pereira RW, Galas D
and Wang K: The complexity, function and applications of RNA in
circulation. Front Genet. 4:1152013.PubMed/NCBI
|
|
60
|
Dasí F, Lledó S, García-Granero E, Ripoll
R, Marugán M, Tormo M, García-Conde J and Aliño SF: Real-time
quantification in plasma of human telomerase reverse transcriptase
(hTERT) mRNA: A simple blood test to monitor disease in cancer
patients. Lab Invest. 81:767–769. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Lledó SM, Garcia-Granero E, Dasí F, Ripoli
R, García SA, Cervantes A and Aliño SF: Real time quantification in
plasma of human telomerase reverse transcriptase (hTERT) mRNA in
patients with colorectal cancer. Colorectal Dis. 6:236–242. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Silva JM, Dominguez G, Silva J, Garcia JM,
Sanchez A, Rodriguez O, Provencio M, España P and Bonilla F:
Detection of epithelial messenger RNA in the plasma of breast
cancer patients is associated with poor prognosis tumor
characteristics. Clin Cancer Res. 7:2821–2825. 2001.PubMed/NCBI
|
|
63
|
Dasí F, Martínez-Rodes P, March JA,
Santamaría J, Martínez-Javaloyas JM, Gil M and Aliño SF: Real-time
quantification of human telomerase reverse transcriptase mRNA in
the plasma of patients with prostate cancer. Ann N Y Acad Sci.
1075:204–210. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Kopreski MS, Benko FA, Kwak LW and Gocke
CD: Detection of tumor messenger RNA in the serum of patients with
malignant melanoma. Clin Cancer Res. 5:1961–1965. 1999.PubMed/NCBI
|
|
65
|
Kopreski MS, Benko FA and Gocke CD:
Circulating RNA as a tumor marker: detection of 5T4 mRNA in breast
and lung cancer patient serum. Ann N Y Acad Sci. 945:172–178.
2001.PubMed/NCBI
|
|
66
|
Chinnappa P, Taguba L, Arciaga R, Faiman
C, Siperstein A, Mehta AE, Reddy SK, Nasr C and Gupta MK: Detection
of thyrotropin-receptor messenger ribonucleic acid (mRNA) and
thyroglobulin mRNA transcripts in peripheral blood of patients with
thyroid disease: Sensitive and specific markers for thyroid cancer.
J Clin Endocrinol Metab. 89:3705–3709. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Turchinovich A, Weiz L and Burwinkel B:
Isolation of circulating microRNA associated with RNA-binding
protein. Methods Mol Biol. 1024:97–107. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Iorio MV and Croce CM: MicroRNAs in
cancer: Small molecules with a huge impact. J Clin Oncol.
27:5848–5856. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Mitchell PS, Parkin RK, Kroh EM, Fritz BR,
Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant
KC, Allen A, et al: Circulating microRNAs as stable blood-based
markers for cancer detection. Proc Natl Acad Sci USA.
105:10513–10518. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K,
Guo J, Zhang Y, Chen J, Guo X, et al: Characterization of microRNAs
in serum: A novel class of biomarkers for diagnosis of cancer and
other diseases. Cell Res. 18:997–1006. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Yu M: Somatic mitochondrial DNA mutations
in human cancers. Adv Clin Chem. 57:99–138. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Chiu RW, Chan LY, Lam NY, Tsui NB, Ng EK,
Rainer TH and Lo YM: Quantitative analysis of circulating
mitochondrial DNA in plasma. Clin Chem. 49:719–726. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Copeland WC, Wachsman JT, Johnson FM and
Penta JS: Mitochondrial DNA alterations in cancer. Cancer Invest.
20:557–569. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Campitelli M, Jeannot E, Peter M,
Lappartient E, Saada S, de la Rochefordière A, Fourchotte V, Alran
S, Petrow P, Cottu P, et al: Human papillomavirus mutational
insertion: Specific marker of circulating tumor DNA in cervical
cancer patients. PLoS One. 7:e433932012. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
van der Vaart M and Pretorius PJ: The
origin of circulating free DNA. Clin Chem. 53:22152007. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Vinay DS, Ryan EP, Pawelec G, et al:
Immune evasion in cancer: Mechanistic basis and therapeutic
strategies. Semin Cancer Biol. 35:S185–S198. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Zou W: Regulatory T cells, tumour immunity
and immunotherapy. Nat Rev Immunol. 6:295–307. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Johnsen AK, Templeton DJ, Sy M and Harding
CV: Deficiency of transporter for antigen presentation (TAP) in
tumor cells allows evasion of immune surveillance and increases
tumorigenesis. J Immunol. 163:4224–4231. 1999.PubMed/NCBI
|
|
80
|
Gabrilovich D: Mechanisms and functional
significance of tumour-induced dendritic-cell defects. Nat Rev
Immunol. 4:941–952. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Dunn GP, Bruce AT, Ikeda H, Old LJ and
Schreiber RD: Cancer immunoediting: From immunosurveillance to
tumor escape. Nat Immunol. 3:991–998. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Lauritzsen GF, Hofgaard PO, Schenck K and
Bogen B: Clonal deletion of thymocytes as a tumor escape mechanism.
Int J Cancer. 78:216–222. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Enninga EA, Nevala WK, Holtan SG and
Markovic SN: Immune reactivation by cell-free fetal DNA in healthy
pregnancies re-purposed to target tumors: Novel checkpoint
inhibition in cancer therapeutics. Front Immunol.
6:4242015.PubMed/NCBI
|
|
84
|
Krieg AM, Yi AK, Matson S, Waldschmidt TJ,
Bishop GA, Teasdale R, Koretzky GA and Klinman DM: CpG motifs in
bacterial DNA trigger direct B-cell activation. Nature.
374:546–549. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Zhang SY, Jouanguy E, Ugolini S, Smahi A,
Elain G, Romero P, Segal D, Sancho-Shimizu V, Lorenzo L, Puel A, et
al: TLR3 deficiency in patients with herpes simplex encephalitis.
Science. 317:1522–1527. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Wölfle SJ, Strebovsky J, Bartz H, Sähr A,
Arnold C, Kaiser C, Dalpke AH and Heeg K: PD-L1 expression on
tolerogenic APCs is controlled by STAT-3. Eur J Immunol.
41:413–424. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Place RF, Li LC, Pookot D, Noonan EJ and
Dahiya R: MicroRNA-373 induces expression of genes with
complementary promoter sequences. Proc Natl Acad Sci USA.
105:1608–1613. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
García-Olmo DC, Domínguez C, García-Arranz
M, Anker P, Stroun M, García-Verdugo JM and García-Olmo D:
Cell-free nucleic acids circulating in the plasma of colorectal
cancer patients induce the oncogenic transformation of susceptible
cultured cells. Cancer Res. 70:560–567. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Mittra I, Khare NK, Raghuram GV, Chaubal
R, Khambatti F, Gupta D, Gaikwad A, Prasannan P, Singh A, Iyer A,
et al: Circulating nucleic acids damage DNA of healthy cells by
integrating into their genomes. J Biosci. 40:91–111. 2015.
View Article : Google Scholar : PubMed/NCBI
|
